Permanent Solutions
Thorough research and an in-depth understanding of the clinical, medical and regulatory functional areas of European life science businesses is key to our success.
Our approach combines the traditional sourcing methods of file research, advertising, referral and search, to provide the broadest choice possible for each assignment on which we act, and almost always on a contingent basis.
However our key talent acquisition tool is discrete targetted headhunting, with over 50% of successfully completed assignments resulting from the consistent application of our proactive search methodology.
As we only service the clinical, medical and regulatory functional areas, our consultants have industry-leading experience and provide a truly consultative service, understanding and shaping your requirements.
We are keenly aware of the legislation that governs our activities in each country in which we are active, and operate strictly within the requirements of such. Additionally, as an ISO 9001:2000 accredited company, we employ a comprehensive quality management system which informs all of our actions and provides a clear framework for service led success.
Vacancy Search
Latest News
Anthera listing confirms weak IPO market
The disappointing public outing for Anthera Pharmaceuticals this week, eventually listing on the Nasdaq at a 50% discount to its proposed price, was not an encouraging sign for those US companies with active IPO filings at the SEC who must now be reassessing their next financing steps.
The weakness of Anthera’s IPO – $54m raised was the lowest since Cumberland Pharmaceuticals cracked open the IPO window last August – mirrors the poor performance of Omeros since it went public in October. Anthera and Omeros are both developmental stage, high risk investment opportunities, similar to five of the six companies currently pursuing an IPO. The one mature company on the list, Prometheus Laboratories, with eight marketed products and annual profits since 2005, therefore appears the standout IPO candidate, but only if it clears up uncertainty over rights to its biggest selling product (see tables below).
Investors still risk averse
Anthera was the fifth US pharmaceutical company to go public since the broader stock market recovery in the second half of 2009.
As the table below shows, the initial optimism that IPOs would start to flow has dampened as the two most recent public offerings, Anthera and Ironwood Pharmaceuticals, have only squeezed onto the market at a significant discount to the proposed price. The average discount between the filed price and the actual list price is 20%, even after some companies had already cut back their price targets.
